← All trials
NCT06107803
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 13, 2023
- Primary completion
- Feb 29, 2024
- Completion date
- Feb 29, 2024
- First posted
- Oct 30, 2023
- Last posted
- Oct 30, 2023
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Minerva NeurosciencesLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.